雷珠单抗玻璃体腔注射治疗脉络膜新生血管的分析OCT

OCT analysis of intravitreal ranibizumab injection for choroidal neovascularization

目的分析评价雷珠单抗(Ranibizumab,商品名Lucentis)玻璃体内注射治疗脉络膜新生血管(CNV)的光学相干断层扫描(OCT)结果。方法采用小样本单中心回顾性研究。脉络膜新生血管患者20例(25眼),门诊确诊后玻璃体腔注射雷珠单抗0.5 mg(0.05 m1),注射后第l、2、3、6个月各随访1次,并在前2个月随访时再注射相同剂量2次。随访时主要检查最佳矫正视力、眼压、裂隙灯观察眼底、OCT检查黄斑中心凹视网膜厚度(CFT)等检查,研究分析患者治疗前后眼底OCT的变化。结果注射雷珠单抗后视力较注射前平均提高:1月(1.43±2.11)行,2月(1.53±2.48)行,3月(1.87±2.29)行,6月(1.67±2.58)行。注射雷珠单抗后的每次随访最佳矫正视力和首次治疗前相比,差异均有统计学意义(P<0.05)。首次注射雷珠单抗治疗后各时间段间的视力差异无统计学意义(P>0.05)。注射雷珠单抗后OCT显示的CFT分别为:1月为301.22±22.93μm,2月为290.17±18.35μm,3月为272.84±31.26μm,6月为262.54±26.82μm。术后1、2、3、6个月随访的CFT与术前对比明显减小,具有统计学差异(P<0.05)。结论 CNV患者玻璃体腔内注射雷珠单抗,可有效减轻黄斑水肿,提高视力,是有效方法之一。

Objetive To analyze the Optical coherence tomograph（OCT） of intravitreal ranibizumab（Lucentis） injection for choroidal neovascularization（CNV）. Methods A small-sample, single-center, retrespective study was adopted. 25 eyes of 20 patients with CNV were included. Treatment protocol consisted of three consecutive intravitreal Ranibizumab（0.5 mg/0.05 ml） per 1 month. The follow time was 1, 2, 3, and 6 months. The best corrected vision acuity, intraocular pressure, fundus, and OCT scanning for central foveal thickness（CFT） were recorded before and after the injection. The CFT and best corrected vision acuity were analyzed before and after the treatment. Results The improvement of best corrected vision acuity were 1.43 ± 2.11, 1.53 ± 2.48, 1.87 ± 2.29, 1.67 ± 2.58 rows after 1, 2, 3, 6 months respectively. Each of them was significant compared with the pre-injection（P 0.05）. However, there was no significance between them（P 0.05）. The CFT were 301.22 ± 22.93, 290.17 ± 18.35, 272.84 ± 31.26, 262.54 ± 26.82 μm after 1, 2, 3, 6 months respectively. Each of them was significant compared with the pre-injection（P 0.05）. Conclusion Intravitreal injection of Ranibizumab for CNV could alleviate macular edema and promote vision acuity. It could be one of effective methods.